drugset
Drugs / rVSVΔG-ZEBOV
last change Sep 2023 re-read 3 minutes ago

rVSVΔG-ZEBOV

also known as ERVEBO · rVSVΔG-ZEBOV-GP · V920

Vaccine

Developed for
Ebola hemorrhagic fever
Investigated by
Centers for Disease Control and Prevention · Department of Health and Human Services · Ministry of Health and Sanitation, Sierra Leone · University of Sierra Leone · eHealth Africa

Trials 1

today NCT02378753 · Ph 2/3
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT02378753 Apr 2015 → Nov 2016 Ebola hemorrhagic fever Centers for Disease Control and Prevention Completed No outcome recorded

Press releases naming this drug 7 releases

DateIssuerRelease
2023-09-07 Merck Sharp & Dohme LLC European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older merck.com ↗
2023-08-03 Merck Sharp & Dohme LLC U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older merck.com ↗
2020-02-14 Merck Sharp & Dohme LLC ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification merck.com ↗
2019-12-20 Merck Sharp & Dohme LLC Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live) merck.com ↗
2019-11-13 Merck Sharp & Dohme LLC ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Awarded Prequalification Status by the World Health Organization (WHO) merck.com ↗
2019-11-11 Merck Sharp & Dohme LLC Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union merck.com ↗
2019-10-18 Merck Sharp & Dohme LLC Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease merck.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as rVSVΔG-ZEBOV ClinicalTrials.gov intervention name — accepted as the source's own label NCT02378753 ↗
Known as ERVEBO “BACKGROUND: ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was...” PMID 36208978 ↗ Oct 2022
Known as rVSVΔG-ZEBOV-GP “BACKGROUND: ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was...” PMID 36208978 ↗ Oct 2022
Known as V920 “The vaccine referred to as V920 is a recombinant vesicular stomatitis virus (rVSV) in which the VSV-G envelope glycoprotein (GP) is completely replaced by the Zaire ebolavirus...” PMID 28647166 ↗ Jun 2017
Modality Vaccine “monovalent recombinant vesicular stomatitis virus Ebola vaccine” NCT02378753 ↗
Route Intramuscular “A single dose of rVSVΔG-ZEBOV will be administered intramuscularly.” NCT02378753 ↗